Asahi Kasei finishes $96M+ pharma excipient manufacturing plant in Japan

15 Feb 2023
endpts.com
Acquisition
The Japanese conglomerate Asahi Kasei has put the finishing touches on a second plant to manufacture the pharma excipient microcrystalline cellulose (MCC) amid a growth in demand. Asahi Kasei today announced it has finished building its plant to manufacture Ceolus, its brand of MCC. The facility is located at the Mizushima Works in the city of Kurashiki, Japan, near Okayama. According to Asahi Kasei’s release, the facility was finished in January of this year and is part of an effort to grow its MCC output due to “substantially growing demand.” The ¥13 billion ($96.8 million) facility broke ground in 2021 and is expected to start production in April of this year. However, other details on the facility, such as the size and the headcount, were not immediately available. Endpoints News reached out to Asahi Kasei but did not get a response by press time. The product itself is a tablet binder made from pulp. The new plant aims to raise the supply capacity for MCC but also provide some stability of supply for its multiple manufacturing sites. The manufacturer also noted that the customers for the product, to be distributed globally, will be other pharmaceutical manufacturers. “The increased capacity at this new plant will enable us to provide a more stable supply of Ceolus for distribution centers around the world to get products to customers in greater quantities. The second plant will make Ceolus more accessible to patients around the world,” said Eiichi Hori, senior general manager of Asahi Kasei’s functional additives division, in a release . Asahi Kasei has been making moves in the wider pharma manufacturing space over the past year as, in April, the manufacturer acquired US-based CDMO Bionova Scientific, netting itself nearly 80,000 square feet of space in California.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.